# Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)

> **NCT00322556** · PHASE3 · COMPLETED · sponsor: **CSL Behring** · enrollment: 55 (actual)

## Conditions studied

- Agammaglobulinemia
- IgG Deficiency
- Common Variable Immunodeficiency

## Interventions

- **DRUG:** Immunoglobulins Intravenous (Human)

## Key facts

- **NCT ID:** NCT00322556
- **Lead sponsor:** CSL Behring
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2008-04
- **Final completion:** 2008-04
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2012-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00322556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00322556, "Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00322556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*